Loading organizations...
Key people at Zoundream AG.
Zoundream AG develops an AI platform translating infant cry sounds into actionable health and developmental information. Its core technology uses advanced sound recognition and proprietary deep learning to identify potential pathologies, pain, or specific needs. This non-invasive method provides physiological insights through auditory biometrics, offering a deeper understanding of an infant's state.
The company was founded in 2019 in Basel, Switzerland, by Roberto Iannone, Matteo Ingravalle, and Ana Laguna Pradas. They initiated Zoundream from the insight that infant cries contain vital diagnostic markers often imperceptible to human perception. The founders applied their expertise in AI and biosignal processing to build this discerning system.
Zoundream’s product offers objective monitoring capabilities for parents and pediatricians alike. Its vision is to establish a new standard in early childhood care, providing caregivers a tool for timely detection of developmental or medical concerns. This ultimately supports improved health and developmental outcomes for infants globally.
Key people at Zoundream AG.
Zoundream AG is a Basel-based health-tech startup founded in 2019 that develops AI-driven tools for analyzing infant cries and vocalizations in real-time.[1][2][5] Its core product translates baby cries to reveal needs like hunger or sleepiness and detects early signs of health issues such as gastrointestinal problems or neurodevelopmental disorders, serving parents, pediatricians, and hardware makers through integrations in baby monitors from Philips Avent, Maxi-Cosi, Motorola Nursery, and Dorel Juvenile.[1][2][3] The non-invasive solution leverages the world's largest cry database and clinical partnerships with institutions like Hospital Clínic Barcelona, University Medical Center Utrecht, and University Children’s Hospital Zurich, recently raising €4 million in seed funding in September 2025 to expand product development, team, and global partnerships.[1][4][8]
This positions Zoundream at the intersection of AI, preventive neonatal care, and consumer hardware, addressing parental stress while enabling early interventions that can profoundly impact infant health outcomes.[3][5]
Zoundream was founded in 2019 in Basel, Switzerland, by Roberto Iannone (CEO), Matteo Ingravalle, and Ana Laguna Pradas, with an engineering center in Barcelona, Spain.[1][2][4] The idea emerged from a mission to decode the "universal language" of baby cries using AI and sound recognition, starting with real-time translation of needs and evolving toward non-invasive monitoring for pathologies.[2][5] Early traction came through building the world's largest cry database, backed by multimodal research incorporating acoustics, EEG, NIRS, and facial expressions, which powered their superior Cry Analysis technology.[3][8] Pivotal moments include partnerships with global baby product brands like Dorel Juvenile in 2023 for product embedding and clinical collaborations across Europe, North/South America, and Asia, culminating in the €4M seed round announced September 26, 2025.[1][2][8]
Zoundream rides the wave of AI-powered preventive healthcare and edge AI in consumer devices, capitalizing on booming demand for smart parenting tools amid rising parental mental health challenges and neonatal care gaps.[2][6] Timing aligns with post-pandemic focus on home-based health monitoring and regulatory tailwinds like the EU AI Act, which Zoundream proactively addresses.[7] Market forces favoring it include explosive growth in baby tech (global brands adopting) and clinician-validated biomarkers from cries, influencing the ecosystem by bridging consumer hardware with medical research—pioneering cry sounds as a scalable health signal and inspiring similar audio-AI diagnostics.[1][3][8]
Zoundream's €4M seed positions it for aggressive scaling: deeper hardware integrations, global clinical trials, and expansions into pathology detection apps for pediatricians.[1][4][8] Trends like multimodal AI (integrating cries with biometrics) and regulatory-compliant health AI will propel growth, potentially evolving it into a platform leader in infant biomarkers. Its influence may expand to shape standards in neonatal tech, empowering families worldwide with actionable insights that start with a cry.
